Estrogen signaling pathway and its imaging in human breast cancer

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1773-1778

  Hayashi, Shin ichi ^a   Niwa, Toshifumi ^a   Yamaguchi, Yuri ^b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAITAMA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; CELL NUCLEUS RECEPTOR; DNA; EARLY GROWTH RESPONSE FACTOR 3; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GONADORELIN AGONIST; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE 6; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOMEDIN BINDING PROTEIN 4;

ACCURACY; BREAST CANCER; DIAGNOSTIC VALUE; DNA MICROARRAY; GENE EXPRESSION PROFILING; HORMONAL THERAPY; HUMAN; IMAGE ANALYSIS; MICROENVIRONMENT; MOLECULAR BIOLOGY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

BREAST NEOPLASMS; ESTROGENS; FEMALE; HUMANS; MOLECULAR BIOLOGY; PROTEOMICS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 70349582788     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01243.x     Document Type: Review

References (42)

1. Kitajima I. Current topics in endocrine therapy for breast cancer. Breast Cancer 2008, 15:253-90.
2. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-68.
3. Veronesi U, Cascinelli N, Greco M. A reappraisal of oophorectomy in carcinoma of the breast. Ann Surg 1987, 205:18-21.
4. Hayashi S. Prediction of hormone sensitivity by DNA microarray. Biomed Pharmacotherapy 2004, 58:1-9.
5. Inoue A, Yoshida N, Omoto Y. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 2002, 9:175-92.
6. Terasaka S, Aita Y, Inoue A. Expression profiling of the estrogen responsive genes for evaluation of estrogen activity among natural estrogens and industrial chemicals. Environ Health Persp Toxicogenomics 2004, 112:773-81.
7. Omoto Y, Eguchi H, Yamaguchi Y, Hayashi S. Estrogen receptor (ER) β1 and ERβcx/β2 inhibit ERα function differently in breast cancer cell line MCF7. Oncogene 2003, 22:5011-20.
8. Inoue A, Omoto Y, Yamaguchi Y, Kiyama R, Hayashi S. Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cell. J Mol Endocrinol 2004, 32:649-61.
9. Yoshida N, Omoto Y, Inoue A. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 2004, 95:496-502.
10. Saji S, Hayashi S, Yoshida N. Therapeutic utility of histone deacetylase 6 regulation via estrogen signaling in human breast cancer MCF-7. Oncogene 2005, 24:4531-9.
11. Zhang Z, Yamashita H, Toyama T. HDAC6 expression is correlated with better prognosis in breast cancer. Clin Cancer Res 2004, 10:6962-8.
12. Mita K, Zhang Z, Ando Y. Prognostic significance of insulin-like growth factor binding protein (IGFBP) -4 and IGFBP-5 expression in breast cancer. Jpn J Clin Oncol 2007, 37:575-82.
13. Suzuki T, Inoue A, Miki Y. Early growth responsive gene 3 (EGR3) in human breast carcinoma: a regulator of estrogen-mediated invasion and a potent prognostic factor. Endocrine-Related Cancer 2007, 14:279-92.
14. Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994, 63:451-86.
15. Matsumoto M, Yamaguchi Y, Seino Y. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocrine-Related Cancer 2008, 15:451-63.
16. Márquez DC, Pietras RJ. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001, 20:5420-30.
17. Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005, 65:3903-10.
18. Santen RJ, Song RX, Masamura S. Adaptation to estradiol deprivation causes up-regulaiton of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 2008, 630:19-34.
19. Yue W, Fan P, Wang J. Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol 2007, 106:102-10.
20. Martin L-A, Farmer I, Johnston SRD, Ali S, Dowsett M. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long term estrogen deprivation. Endocrine-Related Cancer 2005, 12:S75-84.
21. Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, Rae JM. The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat 2009, 115:289-96.
22. Pirog EC, Collins DC. Metablism of dihydrotestosterone in human liver: importance of 3α- and 3β-hydroxysteroid dehydrogenase. Endocrinol Metab 1999, 84:3217-21.
23. Kuiper GGJM, Carlsson B, Grandien KC. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 1997, 138:863-70.
24. Maggiolini M, Donzé O, Jeannin E, Andò S, Picard D. Adrenal androgens stimulate the proliferation of breast cancer cells as direct activators of estrogen receptor α. Cancer Res 1999, 59:4864-9.
25. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nature Rev Cancer 2006, 6:392-401.
26. Allinen M, Beroukhim R, Cai L. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
27. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-601.
28. Yamaguchi Y. Microenvironmental regulation of estrogen signals in breast cancer. Breast Cancer 2007, 14:175-81.
29. O'Neill JS, Miller WR. Aromatase activity in breast adipose tissue from women with benign and malignant breast disease. Br J Cancer 1987, 56:601-4.
30. Santen RJ, Santner SJ, Pauley RJ. Estrogen production via the aromatase enzyme in breast carcinoma: which cell type is responsible?. J Steroid Biochem Mol Biol 1997, 61:267-71.
31. Osborne CK, Shou J, Massarweh S. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistancein breast cancer. Clin Cancer Res 2005, 11:865s-870s.
32. Le Goff P, Montano MM, Schodin DJ. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 1994, 269:4458-66.
33. Kato S, Endoh H, Masuhiro Y. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270:1491-4.
34. Hayashi S, Yamaguchi Y. Estrogen signaling and prediction of endocrine therapy. Cancer Chemother Pharmacol 2005, 56:27-31.
35. Yamaguchi Y, Takei H, Suemasu K. Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Res 2005, 65:4653-62.
36. Yamaguchi Y, Hayashi S. Estrogen-related cancer microenvironment of breast cancer. Endocrine J 2009, 56:1-7.
37. Orimo A, Gupta PB, Sgroi DC. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-48.
38. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003, 17:792-803.
39. Gaggioli C, Hooper S, Hidalgo-Carcedo C. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPase in leading and following cells. Nature Cell Biol 2007, 9:1392-400.
40. Ishii G, Sangai T, Oda T. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem Biophys Res Commun 2003, 309:232-40.
41. Direkze NC, Hodivala-Dilke K, Jeffery R. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 2004, 64:8492-5.
42. Sorlie T, Perou CM, Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 2001, 98:10869-74.